Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly (I-70)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention |
|---|---|
| Cardiomyopathy Coronary Artery Disease Congestive Heart Failure Myocardial Infarction | Device: Implantable Cardioverter Defibrillator Other: Optimal Medical Therapy |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Treatment |
| Official Title: | CSP #592 - Efficacy and Safety of ICD Implantation in the Elderly |
- All-cause mortality [ Time Frame: Up to 24 months ]To determine if a primary prevention strategy with ICD implantation in addition to optimal medical therapy (OMT) is effective in reducing all-cause mortality compared to OMT alone in patients >=70 years of age who are eligible for ICD therapy according to current Centers for Medicare & Medicaid Services (CMS) criteria.
| Estimated Enrollment: | 100 |
| Actual Study Start Date: | August 7, 2015 |
| Estimated Study Completion Date: | August 2018 |
| Estimated Primary Completion Date: | August 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
ICD implantation in addition to optimal medical therapy
|
Device: Implantable Cardioverter Defibrillator
The ICD and lead(s) will be FDA-approved.
|
|
Active Comparator: 2
Optimal Medical Therapy
|
Other: Optimal Medical Therapy
Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
|
Detailed Description:
The overall aim of this trial is to study the safety and efficacy of ICD implantation as a primary prevention strategy of sudden cardiac death (SCD) in patients 70 years and older. In particular, this study is designed to determine the comparative effectiveness of ICD, in addition to optimal medical therapy (OMT), in reducing all-cause mortality, versus OMT alone; OMT includes standard intervention for chronic heart failure patients, i.e. lifestyle modification, disease management, adoption of healthy diet and exercise practices, etcetera. One particularly important secondary objective is to assess treatment efficacy under the conditions of high versus low co-morbidity burden.
Participants will be randomized (1:1 ratio) to ICD + OMT or OMT alone, and stratified by participating site and co-morbidity level (Charlson score <3 versus 3+). Acute treatment visits will occur as clinically indicated and per local convention; follow-up will occur 1-4 months post-randomization (all participants), and not sooner than 30 days - and not later than 120 days post-implantation (ICD arm); regular follow-up will occur at 6 month intervals post-randomization until study close (all participants). All follow-up will be conducted centrally. Neither the participant nor treating clinician will be masked to treatment.
Primary Objective:
The primary objective of this study is to determine if a primary prevention strategy with ICD implantation in addition to optimal medical therapy (OMT) is effective in reducing all-cause mortality compared to OMT alone in patients 70 years of age and older who are eligible for ICD therapy according to current Centers for Medicare & Medicaid Services (CMS) criteria.
Primary Hypothesis:
The primary hypothesis of this study is that implantation of an ICD plus optimal medical therapy will reduce all-cause mortality in patients 70 years of age and older versus optimal medical therapy alone.
Secondary Objectives:
- One secondary objective of this study is to ascertain whether age, co-morbidity burden, or age and burden together, are determinants in mortality outcomes in the OMT versus ICD + OMT group.
- An additional secondary objective of the study is to determine the effect of ICD implantation plus optimal medical therapy on quality of life among elderly patients compared with optimal medical therapy.
Eligibility| Ages Eligible for Study: | 70 Years and older (Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 70 years of age or older
-
Eligible for ICD implementation according to the CMS criteria for primary prevention by one of the following conditions:
- Documented prior MI and a measured left ventricular ejection fraction (LVEF) <=30% (includes New York Heart Association [NYHA] class I, II, or III)
- Coronary artery disease with a documented prior MI, a measured left ventricular ejection fraction <=35%, and inducible, sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) at electrophysiology (EP) study
- Ischemic dilated cardiomyopathy (IDCM), documented prior MI, NYHA class II and III heart failure, and measured LVEF <=35%
- Non-ischemic dilated cardiomyopathy (NIDCM) > 3 months, NYHA Class II and III heart failure, and measured LVEF <=35%
- Stable condition on Optimal Medical Therapy
- Able and willing to provide informed consent to participate in this study
Exclusion Criteria:
- Enrolled in or planning to enroll in a conflicting trial
- Receiving a bi-ventricular ICD device
- New York Heart Association class IV heart failure
- Cardiogenic shock or symptomatic hypotension while in stable baseline rhythm,
- Coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months
- An MI within the past 40 days
- Clinical symptoms or findings that would make them a candidate for coronary revascularization
- Irreversible brain damage from pre-existing cerebral disease
- Any disease other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year
- Circumstance that would prevent completion of the trial and follow-up activities, including medical condition
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT02121158
| Contact: Michael T Wininger, PhD | (203) 932-5711 ext 3262 | michael.wininger@va.gov | |
| Contact: Jane Zhang, PhD | (203) 932-5711 ext 3779 | jane.zhang@va.gov |
| United States, California | |
| VA Palo Alto Health Care System, Palo Alto, CA | Active, not recruiting |
| Palo Alto, California, United States, 94304-1290 | |
| United States, District of Columbia | |
| Washington DC VA Medical Center, Washington, DC | Recruiting |
| Washington, District of Columbia, United States, 20422 | |
| Contact: Steve Singh, MD 202-745-8115 steve.singh@va.gov | |
| Contact: Suzanne McNicholas (202) 745-5223 suzanne.mcnicholas@va.gov | |
| Study Chair: Steve Singh, MD | |
| United States, Florida | |
| North Florida/South Georgia Veterans Health System, Gainesville, FL | Recruiting |
| Gainesville, Florida, United States, 32608 | |
| Contact: Matthew McKillop, MD 352-376-1611 ext 4457 matthew.mckillop@va.gov | |
| United States, Minnesota | |
| Minneapolis VA Health Care System, Minneapolis, MN | Recruiting |
| Minneapolis, Minnesota, United States, 55417 | |
| Contact: Selcuk Adabag, MD 612-467-3655 selcuk.adabag@va.gov | |
| United States, Oregon | |
| VA Portland Health Care System, Portland, OR | Recruiting |
| Portland, Oregon, United States, 97239 | |
| Contact: Karen MacMurdy, MD 503-220-8262 karen.macmurdy@va.gov | |
| United States, Tennessee | |
| Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Recruiting |
| Nashville, Tennessee, United States, 37212-2637 | |
| Contact: Pablo Saavedra, MD 615-873-6940 pablo.saavedra@va.gov | |
| Study Chair: | Steve Singh, MD | Washington DC VA Medical Center, Washington, DC |
More Information
| Responsible Party: | VA Office of Research and Development |
| ClinicalTrials.gov Identifier: | NCT02121158 History of Changes |
| Other Study ID Numbers: |
592 |
| Study First Received: | April 16, 2014 |
| Last Updated: | February 24, 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Keywords provided by VA Office of Research and Development:
|
CSP 592 ICD cardiovascular heart aging chronic diseases multi-site trial phase 3 investigational device |
cardiomyopathy coronary artery disease congestive heart failure myocardial infarction I-70 I70 elderly defibrillator |
Additional relevant MeSH terms:
|
Heart Failure Infarction Coronary Artery Disease Myocardial Ischemia Coronary Disease Myocardial Infarction Cardiomyopathies Heart Diseases |
Cardiovascular Diseases Ischemia Pathologic Processes Necrosis Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on July 17, 2017


IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
